showed a trendP =0.079
Regarding patients with LNM, initial treatment including EBRT showed a trend to favorable survival than sorafenib (1-year OS rates: 16.3% vs 6.4%, P =0.079). 32 The statistical analysis might be underpowered due to the small numbers of patients with LNM, and additional data from 2013 to 2014 are being added and analyzed.